Standard InChI: InChI=1S/C26H30ClFN2O4S/c1-15(2)22(35)23(31)30-26(11-3-4-12-26)25(34)29-21(24(32)33)13-16-5-7-17(8-6-16)18-9-10-20(28)19(27)14-18/h5-10,14-15,21-22,35H,3-4,11-13H2,1-2H3,(H,29,34)(H,30,31)(H,32,33)/t21?,22-/m0/s1
1.Tanneeru K, Sahu I, Guruprasad L. (2013) Ligand-based drug design for human endothelin converting enzyme-1 inhibitors, 22 (9):[10.1007/s00044-012-0433-z]
2.Umekawa, K K and 5 more authors. 2000-09 Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. [PMID:11043447]
3.Inguimbert, Nicolas N and 6 more authors. 2002-03-28 Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP). [PMID:11906289]
4.Berger, Yann Y and 6 more authors. 2005-01-27 Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. [PMID:15658862]
5.Seed, Alison A and 8 more authors. 2012-10-15 The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. [PMID:22480515]
6.McKinnell, R Murray RM and 13 more authors. 2019-01-10 Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI). [PMID:30655952]